enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Ruxolitinib - Wikipedia

    en.wikipedia.org/wiki/Ruxolitinib

    Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11] [12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; [6] [13] and steroid-refractory ...

  3. JakafiĀ® (ruxolitinib) Prescribing Information Updated with ...

    www.aol.com/news/2013-06-12-jakafi-ruxolitinib...

    The prescribing information for Jakafi now includes a new recommended starting dose of 5 mg twice daily of Jakafi for patients with baseline platelet counts between 50-100 x 10 9 /L (50,000 to ...

  4. Primary myelofibrosis - Wikipedia

    en.wikipedia.org/wiki/Primary_myelofibrosis

    In November 2011, the US Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) as a treatment for intermediate or high-risk myelofibrosis. [24] [25] Ruxolitinib serves as an inhibitor of JAK 1 and 2. Data from two phase III studies of ruxolitinib showed that the treatment significantly reduced spleen volume, improved symptoms of ...

  5. FDA approves Incyte's treatment for chronic graft-versus-host ...

    www.aol.com/news/fda-approves-incytes-treatment...

    Jakafi is approved in the U.S. for treating acute GvHD and is considered a remedy for certain bone marrow and blood d FDA approves Incyte's treatment for chronic graft-versus-host disease Skip to ...

  6. New Data for Jakafi® (ruxolitinib) Presented at the 2012 ...

    www.aol.com/news/2012-12-10-new-data-for-jakafi...

    In this study, where twice as many patients were randomized to Jakafi (146) as to placebo (73), there were 14 percent (n=20) deaths in the group treated with Jakafi and 22 percent (n=16) in the ...

  7. Tofacitinib - Wikipedia

    en.wikipedia.org/wiki/Tofacitinib

    [10] [11] In 2019, the safety committee of the European Medicines Agency began a review of tofacitinib and recommended that doctors temporarily not prescribe the 10 mg twice-daily dose to people at high risk for pulmonary embolism. [12] The U.S. Food and Drug Administration (FDA) also released warnings about the risk of blood clots.

  8. Beers criteria - Wikipedia

    en.wikipedia.org/wiki/Beers_Criteria

    The Beers Criteria for Potentially Inappropriate Medication Use in Older Adults, commonly called the Beers List, [1] are guidelines published by the American Geriatrics Society (AGS) for healthcare professionals to help improve the safety of prescribing medications for adults 65 years and older in all except palliative settings.

  9. AOL Mail

    mail.aol.com/?icid=aol.com-nav

    Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!